Experience

Altamira Therapeutics

• Bermuda
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Senior Business Advisor (US)

  • Apr 2023 - 9 months

  Basel, Switzerland Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets.



FarmaMondo Group

• Switzerland
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Senior Business Advisor (US)

  • May 2022 - 1 year 8 months

  Chiasso, Switzerland We are a fast-growing, Swiss-based pharmaceutical group focused on providing market access and specialty distribution services through a unique infrastructure and geographical footprint. We aim to give patients easier access to both licensed and unlicensed medicines.



novAIZen

• CBO (fractional)

  • Nov 2021 - 2 years 2 months

  Baltimore, Maryland, United States Brain disorders remain the biggest challenge at human frontiers. We are building and employing a Deep Machine Learning Platform "Darwin" to discover therapeutic nodes in existing genetic and biochemical data sets. We are rethinking medicine using deep machine learning strategies.



Zepteon, Inc.

• United States
• Biotechnology Research

• Head of BD (fractional)

  • Jun 2020 - 3 years 7 months

  Boston, MA Zepteon, Inc. is a privately held corporation that has developed first-in-class chromatography resins capable of separating antibodies and Fc-fusions with specific glycoforms that can more potently combat infectious diseases, cancer, autoimmunity and rare diseases.



selected past engagements

• Business Advisor, Strategic Advisor, fractional CXO

  • Jun 2012 - Aug 2023

  Greater Boston Area and beyond Functioned as Head of BD, fractional CXO, strategic or business advisor for life sciences companies. Drove strategic partnering and negotiated transactions. Developed and executed financing and growth strategy. • Paramount BioPharma (cancer Tx; CEO; 2023); Riparian Pharmaceuticals (cardiovascular Tx; 2022-2023); KernalBio (mRNA Tx; CBO; 2021-2022), AstraDx (machine vision Dx; 2021-2022), Avilar Therapeutics (targeted protein degradation; 2020-2022), Travera (cancer Dx; 2020), QurAlis (ALS… Show more Functioned as Head of BD, fractional CXO, strategic or business advisor for life sciences companies. Drove strategic partnering and negotiated transactions. Developed and executed financing and growth strategy. • Paramount BioPharma (cancer Tx; CEO; 2023); Riparian Pharmaceuticals (cardiovascular Tx; 2022-2023); KernalBio (mRNA Tx; CBO; 2021-2022), AstraDx (machine vision Dx; 2021-2022), Avilar Therapeutics (targeted protein degradation; 2020-2022), Travera (cancer Dx; 2020), QurAlis (ALS therapeutics; 2017-2021), Genevant (RNA drug delivery; Head of BD; 2019-2020), EnClear Therapies (CNS drug delivery; 2018-2020), Dicerna Pharmaceuticals (RNAi therapeutics; 2015, 2016-2019), Albireo Pharmaceuticals (orphan disease therapeutics; 2018-2019), Q-State BioSciences (CNS drug discovery; 2015-2017), Phosphorex (drug delivery; 2015-2017; 2022): Initiated, negotiated and closed licensing and other strategic partnerships. Supported financing. Defined corporate strategy. • IsoPlexis (multiplex Dx; Head of BD; 2015-2016), Windgap Medical (epinephrine autoinjector; 2014-2016) and SQZ Biotech (drug delivery; 2014-2015): Negotiated collaborative and license agreements. Advised on additional transactions. • Juniper Pharmaceuticals (formerly, Columbia Laboratories, specialty pharma; 2014-2015): Spearheaded new product development function. Developed 505b2 asset strategy. Helped negotiate transaction. • AesRx (orphan disease therapeutics; Business Advisor, 2012-2014): Supported CEO in progressing acquisition by Baxter. Achieved competitive financing. • Harvard University Office of Technology Development (Director, Business Development, 2012): Prioritized portfolio of licensing opportunities and commenced agreement negotiations. Show less



Radius Health, Inc.

• United States
• Pharmaceutical Manufacturing
• 100 - 200 Employee

• Director, Business Development

  • Nov 2007 - Feb 2012

  Cambridge, MA Functioned in broad role across multiple disciplines, including partnering and operations. • Identified 3M’s transdermal delivery technology for Radius’ osteoporosis compound and negotiated feasibility, development and clinical supplies agreements with 3M Drug Delivery. Asset advanced to Phase 2 clinical studies. • Accelerated clinical development of Phase 2 and 3 compounds by closing transactions with vendors and suppliers. Served as business point person on alliances. • Recommended… Show more Functioned in broad role across multiple disciplines, including partnering and operations. • Identified 3M’s transdermal delivery technology for Radius’ osteoporosis compound and negotiated feasibility, development and clinical supplies agreements with 3M Drug Delivery. Asset advanced to Phase 2 clinical studies. • Accelerated clinical development of Phase 2 and 3 compounds by closing transactions with vendors and suppliers. Served as business point person on alliances. • Recommended partners and estimated deal sizes for clinical-stage compounds. Helped complete >$500 million option licensing agreement in osteoporosis with Novartis. Structured and negotiated material transfer and collaboration agreements to explore new therapeutic indications and delivery options. Show less



Predictive Biosciences, others

• Business Development Consultant

  • Jan 2007 - Oct 2007

  Supported companies in licensing, commercial strategy, fundraising and competitive positioning in the US and abroad. • Large Japanese pharmaceutical company: Identified licensees for platform technology. • Assay CRO and drug developer: Identified deal comparables and assigned optimal timing to license clinical-stage compound. Recommended deal structures for board approval. • Predictive Biosciences: Provided strategic analyses regarding the company's diagnostic tests.



Dyax

• Biotechnology Research
• 1 - 100 Employee

• Associate Director, Business Development

  • Jun 2005 - Dec 2006

  Cambridge, MA Identified licensing opportunities and negotiated agreements with Biotechs and universities. Managed alliances. • Negotiated in-licensing and co-development agreements in the areas of oncology, pulmonary and inflammatory diseases, thereby broadening pipeline and disease focus. Functioned as joint steering committee member on alliances. • Created new process to identify, evaluate and integrate therapeutic approaches to expand pipeline. • Recommended assets for clinical development based… Show more Identified licensing opportunities and negotiated agreements with Biotechs and universities. Managed alliances. • Negotiated in-licensing and co-development agreements in the areas of oncology, pulmonary and inflammatory diseases, thereby broadening pipeline and disease focus. Functioned as joint steering committee member on alliances. • Created new process to identify, evaluate and integrate therapeutic approaches to expand pipeline. • Recommended assets for clinical development based on commercial feasibility assessments. Show less



IRL BioPharm

• New Zealand
• Biotechnology Research
• 1 - 100 Employee

• Intern, Business Development

  • Oct 2004 - Mar 2005

  Wellington, New Zealand, and Cambridge, MA Created out-licensing strategy and market forecast for antibody-drug-conjugates in cancer, including funding needs. Recommended business model for a new division.



MIT Entrepreneurship Center

• Team Member, New Enterprises

  • Jan 2004 - Jun 2004

  Cambridge, MA Supported commercialization of a medical device for pain treatment. Wrote business plan, created investor presentations and drafted operating plan. Materials used to build business and attract funding.



Massachusetts General Hospital/Harvard Medical School

• Research Fellow

  • Jun 2002 - May 2004

  Boston, MA Published in Proceedings of the National Academy of Sciences, Neuron and Neuropharnacology. Attended meetings of the Society for Neuroscience and Gordon Research Conferences.